Trichostatin A and Myostatin: Why This HDAC Inhibitor Raises Myostatin, Not Lowers It

The headline most blogs miss: trichostatin A actually turns myostatin on. The molecule is a histone deacetylase (HDAC) inhibitor that has been studied as a possible muscle protector, but the cleanest in-vitro paper shows it activates myostatin transcription, not silences it.

Trichostatin A and myostatin at a glance

This is a corrective piece. The category-level claim that "HDAC inhibitors lower myostatin" rests on a single line of studies in regenerating muscle, while contradicting in-vitro and unloading data sit right next to it.

The takeaway is that TSA's effect on the myostatin pathway is context-dependent and sometimes the opposite of what the muscle-growth supplement world claims.

For pathway basics, read the myostatin overview and the myostatin protein primer. For the broader category, see the myostatin blocker explainer and the natural myostatin inhibitor review.

What trichostatin A actually is

It is a fungal natural product. Trichostatin A (CAS 58880-19-6) was first isolated from Streptomyces hygroscopicus. Chemically it is a hydroxamic acid derivative.

In the cell, TSA reversibly inhibits both class I (HDAC1, 2, 3, 8) and class II (HDAC4, 5, 6, 7, 9, 10) histone deacetylases. That hyperacetylates histones and many non-histone proteins, opening up chromatin and changing gene expression broadly.

In labs it is a standard tool compound at the 100 nM to 1 μM range. It is not a clinical drug — its closest relatives that did reach humans are vorinostat (SAHA) and panobinostat, both used in specific cancers, not muscle medicine.

The hopeful early story: TSA, follistatin, and muscle protection

This is where the "HDAC inhibitor = myostatin blocker" idea started. Around 2004–2006, multiple papers showed that in regenerating or dystrophic muscle, TSA and similar HDAC inhibitors increased follistatin expression.

Since follistatin binds and neutralizes myostatin, the indirect interpretation was clean: more follistatin → less effective myostatin → bigger and healthier muscle.

That story showed up in:

• Dystrophic mouse models, where TSA preserved muscle architecture.
• Aging muscle work, where short courses appeared to support regeneration.
• Several reviews of follistatin's biology.

That is the version most fitness blogs absorbed. But more careful in-vitro work complicated the picture.

The 2010 Wiley paper: TSA actually activates myostatin transcription

This is the part the popular story skipped. Lu and colleagues published in the Journal of Cellular Biochemistry in 2010 a tightly controlled experiment in differentiated C2C12 myocytes (a standard mouse muscle cell line).

The setup was specific: differentiated myotubes, treatment with TSA at 100 nM and 1 μM ranges, then measurement of myostatin promoter activity and endogenous myostatin mRNA.

Findings:

• TSA significantly increased myostatin promoter activity.
• Myostatin mRNA went up.
• The induction depended on ASK1-MKK3/6-JNK and p38 MAP kinase signaling.

In other words, the same drug that increases follistatin in regenerating muscle directly turns up the myostatin gene in differentiated muscle cells. That is not what a "myostatin blocker" looks like.

A separate 2011 paper in Biochemical and Biophysical Research Communications (the Sciencedirect entry above) found that TSA enhanced myogenesis in C2C12 but found "no significant differences in follistatin expression between TSA-treated and non-treated cells." Different lab, different exact protocol, opposite conclusion on follistatin.

Both results can be true if the system is delicate enough that fiber type, time point, and cell state all matter. Which is itself the warning.

The 2015 unloaded-muscle paper: anti-atrophy without myostatin

The bigger 2015 paper used live animals, not cells. Beharry and colleagues, in the Journal of Applied Physiology, used a 14-day hindlimb unloading model — the standard for studying disuse atrophy from bedrest or spaceflight.

Hindlimb unloading caused a 38 percent loss of soleus mass. With TSA treatment, that loss was cut to 25 percent. Type I and IIa fiber size loss was partly prevented, and the slow-to-fast fiber-type shift was reversed.

But the mechanism is the surprise:

• Myostatin gene expression was unchanged by either unloading or TSA.
• Follistatin protein was unchanged.
• TSA suppressed MuRF1 (a key ubiquitin ligase driving protein breakdown).
• Foxo3 transcription factor was unaffected.
• Oxidative-stress markers (glutathione ratio, catalase) shifted toward the normal range.

So in that model, TSA protected muscle through the ubiquitin-proteasome and redox pathways, not through myostatin. Which strongly contradicts the simple "HDAC inhibitors lower myostatin" claim for unloading and bedrest-like scenarios.

Why HDAC inhibitors as a class do not reliably block myostatin

Three reasons, plainly stated:

1. HDAC inhibitors hyperacetylate hundreds of proteins. They will not selectively close one gene. Whether myostatin goes up or down depends on cell state, fiber type, time course, and which co-regulators are present.
2. In regenerating muscle, HDAC inhibition can raise follistatin, but in mature myotubes the same drug can raise myostatin transcription.
3. In whole animals undergoing disuse, the muscle-protective effects of TSA do not require myostatin changes at all.

That is incompatible with the slogan "HDAC inhibitor = myostatin blocker."

What this means for "HDAC inhibitor" supplements

Several legal supplements get marketed as HDAC inhibitors for muscle. The most common are:

• Sulforaphane (from broccoli sprouts).
• Sodium butyrate or butyric acid.
• Diallyl disulfide (from garlic).
• Some flavonoids.

Each one has a real biochemistry story, but the leap from "weak in-vitro HDAC inhibition" to "lowers myostatin in your body" is mostly marketing.

Honest read:

• Sulforaphane has real cardiovascular and detoxification data, weak human muscle data.
• Sodium butyrate is mostly a gut and metabolic intervention, not a reliable muscle builder.
• None of these have human muscle-growth trials matching the strength of the creatine literature.

If a supplement page sells "HDAC inhibition" as its main muscle hook, treat that as a flag, not an endorsement.

Where TSA could still matter

Two niche uses look more plausible than the supplement claim:

1. Muscle disuse and bedrest: TSA-like drugs may protect muscle through MuRF1 suppression and oxidative-stress modulation. The 2015 paper is the cleanest example. This is laboratory work, not a take-this-pill recommendation.
2. Specific muscular dystrophies: HDAC inhibition combined with follistatin upregulation in regenerating muscle has been part of the academic conversation in Duchenne and related conditions. Drug programs in this area use compounds like givinostat, not TSA, and the regulatory status varies.

None of that justifies an over-the-counter supplement marketed as TSA-like for muscle growth.

What actually moves myostatin

The boring stack still wins. Things with stronger human data for either lowering myostatin or improving the follistatin-to-myostatin ratio:

• Resistance training, 2–3 sessions per week, drops myostatin around 20–37 percent over 8–12 weeks.
• Adequate protein, 1.2–1.6 g per kg per day.
• Creatine monohydrate, 3–5 g per day.
• Sleep, 7–9 hours.
• Possibly epicatechin — small human pilot data only.
• Cardio plus strength, combined.

A would-be biohacker is better off building that stack than chasing TSA derivatives.

Pharmacology, dosing, and safety

There is no human muscle dose for TSA. It is a laboratory tool compound. Studies in animals use intraperitoneal injection or implanted pumps at micrograms-per-kg ranges, and side effects can include thrombocytopenia, fatigue, and gastrointestinal toxicity at chronic exposure, mirroring the clinical HDAC-inhibitor class.

Anyone selling TSA powder for personal muscle use is operating outside any reasonable safety frame.

For people who want real anti-myostatin pharmacology, the clinical pipeline has apitegromab, bimagrumab, taldefgrobep alfa, and ACE-031, all studied in proper trials. None of those use HDAC inhibition.

What the field still does not know

Open questions worth flagging:

• Whether selective HDAC inhibitors (HDAC4-only, HDAC6-only) might cleanly reduce myostatin without TSA's complex effects.
• Whether short, intermittent dosing in disuse scenarios (bedrest, ICU stay) gains net muscle protection.
• Whether the follistatin-vs-myostatin tilt depends on muscle fiber type more than drug exposure.
• Whether trichostatin A's effect on tendon and bone tracks the muscle data.

Treat anyone selling certainty on these points with suspicion.

Sources and notes

This article was built from DuckDuckGo and Bing SERP review, full-page competitor checks, and current evidence sources:

• Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy (J Appl Physiol, 2015)
• Transcription activation of myostatin by trichostatin A in differentiated C2C12 myocytes (J Cell Biochem, 2010)
• Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors (ScienceDirect, 2011)
• Trichostatin A | PubChem CID 444732
• Acute inhibition of myostatin-family proteins preserves skeletal muscle (ScienceDirect, 2010)
• Myostatin and its Regulation (Frontiers in Physiology, 2022)
• Myostatin - Wikipedia

Frequently Asked Questions